Susan J. Ward
Nessuna posizione attualmente
Profilo
Dr. Susan J.
Ward is on the Board of Directors at Provasculon, Inc.
Dr. Ward was previously employed as Senior Vice President & Corporate Officer by Millennium Pharmaceuticals, Inc., Vice President-Research by Wyeth Research, a Principal by Sterling Drug, Inc., and Independent Director by SelectX Pharmaceuticals, Inc.
She received her undergraduate degree from The University of Manchester, a graduate degree from The University of Manchester, and a doctorate degree from The University of Manchester.
Precedenti posizioni note di Susan J. Ward
| Società | Posizione | Fine |
|---|---|---|
Provasculon, Inc.
 Provasculon, Inc. Pharmaceuticals: MajorHealth Technology Provasculon, Inc. developed new treatments for chronic wounds and cardiovascular diseases. The company was founded by Thomas Lee Richard and Vincent M. Segers in 2008 and was headquartered in Boston, MA. | Direttore/Membro del Consiglio | - |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| Sterling Drug, Inc. | Corporate Officer/Principal | - |
Wyeth Research
 Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | - |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Direttore/Membro del Consiglio | - |
Formazione di Susan J. Ward
| The University of Manchester | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 5 |
|---|---|
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Health Technology |
| Sterling Drug, Inc. | Consumer Non-Durables |
Wyeth Research
Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Commercial Services |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Provasculon, Inc.
Provasculon, Inc. Pharmaceuticals: MajorHealth Technology Provasculon, Inc. developed new treatments for chronic wounds and cardiovascular diseases. The company was founded by Thomas Lee Richard and Vincent M. Segers in 2008 and was headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Susan J. Ward
